



NDA 50586/S-032

**SUPPLEMENT APPROVAL**

Allergan Pharmaceutical  
Attention: Emily Wawro, MPH  
Sr Analyst, Global Regulatory Affairs  
2525 Dupont Drive  
PO Box 19534  
Irvine, CA 92623

Dear Ms. Wawro:

Please refer to your Supplemental New Drug Application (sNDA) and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for:

<b>NDA/Supplement number</b>	<b>Name</b>	<b>Date submitted</b>	<b>Date Received</b>
NDA 50586/S-032	PRED-G (gentamicin sulfate/prednisolone acetate ophthalmic suspension) 0.3%/1%	December 13, 2017	December 13, 2017

This Prior Approval supplemental new drug application provides for the addition of “blurry vision” to the ADVERSE REACTIONS section of the Package Insert.

**APPROVAL & LABELING**

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text, which is identical to the package insert submitted on May 23, 2018.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling text for the package insert, with the addition of any labeling changes in pending “Changes Being Effectuated” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Dheera Semidey, Regulatory Project Manager, at (301) 796-3009.

Sincerely,

*{See appended electronic signature page}*

Wiley A. Chambers, MD  
Deputy Director  
Division of Transplant and Ophthalmology Products  
Center for Drug Evaluation and Research

ENCLOSURE(S):  
Content of Labeling

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

WILEY A CHAMBERS  
06/07/2018